TIP
PFE icon

Tandem Investment Partners’s Pfizer PFE Stock Holding History

Tandem Investment Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,360
Closed -$289K – 71
2025
Q3 		$289K Sell
11,360
-255
-2% -$6.29K 0.24% 64
2025
Q2 		$282K Buy
11,615
+1,385
+14% +$32.3K 0.25% 62
2025
Q1 		$259K Buy
10,230
+95
+0.9% +$2.49K 0.26% 60
2024
Q4 		$269K Buy
+10,135
New +$275K 0.26% 56

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Tandem Investment Partners's PFE Position: Q4 2025 in Review

Tandem Investment Partners sold out of Pfizer (PFE) in Q4 2025, closing a stake of 11,360 shares — an estimated $289K sold.

Tandem Investment Partners first reported a position in PFE in Q4 2024 and held it in 4 quarters. The position peaked at $289K in Q3 2025. 2,915 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Tandem Investment Partners reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Tandem Investment Partners sold 11,360 Pfizer shares in Q4 2025, an estimated $289K.
  • Tandem Investment Partners first reported a position in Pfizer in Q4 2024 and held it in 4 quarters.
  • Tandem Investment Partners's Pfizer position peaked at $289K in Q3 2025.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Tandem Investment Partners's 13F filing for Q4 2025, filed 21 Jan 2026.